What does this research mean for the field?

1,5-Anhydroglucitol aggravates acute liver failure via the PPARα signaling pathway. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the effects and underlying mechanisms of 1,5-anhydroglucitol on acute liver failure.

synapse

⌘+K

synapse

⌘+K

March 1, 2026Open Access

1,5-Anhydroglucitol Aggravates Acute Liver Failure via the PPARα Signaling Pathway

Key Points

To investigate the effects and underlying mechanisms of 1,5-anhydroglucitol on acute liver failure.
Analyzed clinical outcomes related to 1,5-anhydroglucitol levels in liver failure patients.
Examined the role of PPARα signaling in the context of acute liver failure.
Conducted comparative assessments of hepatic injury in controlled settings.
Identified a significant correlation between 1,5AG levels and liver failure outcomes.
Demonstrated that 1,5AG aggravates hepatic injury through activation of the PPARα signaling pathway.
Highlighted the potential for targeting PPARα in therapeutic approaches to acute liver failure.

Abstract

Acute liver failure (ALF) is a severe hepatic injury associated with high short-term mortality. Our previous study found that 1,5-anhydroglucitol (1,5AG) levels correlate with clinical outcomes in patients with liver failure. This study aimed to explore the potential effects and mechanisms of 1,5AG in ALF.

Bookmark

View Full Paper

Bookmark

View Full Paper

1,5-Anhydroglucitol Aggravates Acute Liver Failure via the PPARα Signaling Pathway

Key Points

Abstract

Cite This Study